| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06158824664095c4ef3c1ab227428d87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b3ce34aa8522cc238a09040c4079a31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-16 |
| filingDate |
2017-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08194af72229cbf03a2bfb84e1114842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1bda969eec6e50f472d4b7bbe8f4953
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_917e993103ce5bc78acd1b62d2c2a2a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09e7f9f8c101c4001c7502b2118d7516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4848c8ca5c6d20da04583be16441f677
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e14778d78f685f79c9da3d3f73c10d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70bab205323d017625f62216608aa3d6 |
| publicationDate |
2017-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017137895-A1 |
| titleOfInvention |
New dendrimeric pyrrolidines, their synthesis and medical use |
| abstract |
The subject-matter of the present invention relates to the synthesis of new dendrimeric molecules based on polyhydroxylated pyrrolidines obtained by means of Click Chemistry reactions. The proposed molecules inhibit the enzymes N-acetylgalactosamine-6-sulfatase (GALNS), iduronate-2-sulfatase (IDS), a-mannosidase and β-glucosidase, deficient in lysosomal storage diseases. The presentation of multivalent iminosugars on a scaffold is a prerequisite for the inhibitory activity as the corresponding monomers are not active. The inhibitory activity reported is the basis for the development of the first-ASSC pharmacological chaperones proposed for the treatment of the above mentioned pathologies. Formula (I) |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-3084364-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020021032-A1 |
| priorityDate |
2016-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |